返回
Multidrug-resistant tuberculosis
DOI:10.1038/s41572-024-00504-2.png)
摘要
En 中文
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa. Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a fluoroquinolone, and extensively drug-resistant TB (XDR-TB) isolates are additionally resistant to other key drugs such as bedaquiline and/or linezolid. Collectively, these subgroups are referred to as drug-resistant TB (DR-TB). All forms of DR-TB can be as transmissible as rifampicin-susceptible TB; however, it is more difficult to diagnose, is associated with higher mortality and morbidity, and higher rates of post-TB lung damage. The various forms of DR-TB often consume >50% of national TB budgets despite comprising <5-10% of the total TB case-load. The past decade has seen a dramatic change in the DR-TB treatment landscape with the introduction of new diagnostics and therapeutic agents. However, there is limited guidance on understanding and managing various aspects of this complex entity, including the pathogenesis, transmission, diagnosis, management and prevention of MDR-TB and XDR-TB, especially at the primary care physician level.
Keyword:
ACQUIRED DRUG-RESISTANCE
DOSE-RANGING TRIAL
MYCOBACTERIUM-TUBERCULOSIS
TREATMENT OUTCOMES
PULMONARY TUBERCULOSIS
LOPINAVIR-RITONAVIR
TREATMENT REGIMENS
RISK-FACTORS
BEDAQUILINE
IMPACT
期刊
N
IF:
60.6
论文数:
650
被引数:
3.8W
机构
引用论文
A Palindromic CpG-Containing Phosphodiester Oligodeoxynucleotide as a Mucosal Adjuvant Stimulates Plasmacytoid Dendritic Cell-Mediated TH1 Immunity
PLoS ONE
IF0
The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot耐多药结核分枝杆菌在耐药热点中的相对传播适合度
NATURE COMMUNICATIONS
IF15.7

